[American Diabetes Association](https://diabetes.org)

April 28, 2026 (Letter of Intent) | June 24, 2026 (Full proposal, invited only)

Up to $200,000/year (including 10% indirect costs), max $600,000 over 3 years.

Supports innovative, human-focused research to advance the cure, prevention, or treatment of Type 1 diabetes by translating discoveries into clinical application.

LOI required; only invited applicants may submit full proposals.

--- ## Description This award supports clinical or translational research with novel hypotheses or approaches that directly involve human subjects, samples, or data to advance the cure, prevention, or treatment of Type 1 diabetes (T1D). Projects should accelerate the translation of scientific discoveries into clinical application and demonstrate significant promise for improving outcomes, reducing treatment burden, or transforming management of T1D. The program prioritizes work that can move promising ideas from the laboratory to real-world clinical impact. --- ## Due Dates - **April 28, 2026:** Letter of Intent (LOI) submission deadline (by 5:00 PM Eastern Time) - **June 24, 2026:** Full proposal submission deadline (invited applicants only; by 5:00 PM Eastern Time) Applicants must first submit an LOI; only those invited may submit a full proposal. --- ## Funding Amount - Up to **$200,000 per year** (including up to 10% indirect costs) - Maximum total: **$600,000 over three years** - Award duration: up to 3 years --- ## Eligibility - Applicants must hold a **full-time independent faculty position or equivalent** at a U.S. university, university-affiliated, or other non-profit research institution. - Less than full-time appointments are considered on a case-by-case basis (must be justified in the application). - Applicants from non-university institutions must provide a letter explaining equivalency to traditional faculty roles. - Must have legal permission to work in the U.S. (citizens, permanent residents, or appropriate work visas/permits). - Only one Principal Investigator is allowed per application (no co-PIs). - Institutional confirmation of work permission is required at the time of application. - There are no specific citizenship requirements beyond work authorization. --- ## Application Process 1. **Letter of Intent (LOI):** - Submit electronically via the ADA's [SmartSimple system](https://diabetes.us-2.smartsimple.com/s_Login.jsp?lang=1&prole=0). - Use the [ICTS LOI Application Instructions](https://professional.diabetes.org/sites/dpro/files/2026-03/icts-loi-application-instruction-t1d2026.pdf) and [LOI Table of Contents Template](https://professional.diabetes.org/sites/dpro/files/2026-03/icts-loi-table-of-contents-t1d2026.docx). - LOI must directly address the RFA scope; non-aligned LOIs will not advance. - LOIs must follow strict formatting and content guidelines. 2. **Full Proposal:** - By invitation only, following review of the LOI. - Full proposals must be submitted using the [ICTS Full Proposal Instructions](https://professional.diabetes.org/sites/dpro/files/2026-03/icts-full-proposal-instructions-t1d2026.pdf) and [Full Proposal Table of Contents Template](https://professional.diabetes.org/sites/dpro/files/2026-03/icts-fp-table-of-contents-t1d2026.docx). - Application must include detailed research plan, budget, biosketch, data/resource sharing plan, and required institutional assurances. 3. **Submission Requirements:** - All applications must be routed through and approved by the applicant’s institution. - Only electronic submissions through SmartSimple are accepted. - Strict adherence to page limits, formatting, and required documents is enforced. - Applications not meeting eligibility or formatting requirements will be administratively disapproved. --- ## Additional Information - **Indirect costs**: Capped at 10% of direct costs, including any subcontracts. - **Principal Investigator salary**: Cannot exceed 20% of the total budget (direct + indirect costs). - **Data and resource sharing**: Required within 6 months of publication or 18 months post-award if unpublished; waiver possible only for specific reasons. - **Artificial Intelligence Policy**: Only limited, non-substantive AI use is permitted (e.g., grammar, formatting); scientific content must be original work. Formal disclosure required if AI is used. - **No co-Principal Investigators**: Only one PI per application. - **Institutional assurances**: IRB/IACUC approval required for human/animal research before award activation. - **Contact ADA Research Programs staff** for eligibility questions or technical assistance. --- ## External Links - [Program page & application portal](https://professional.diabetes.org/research-grants/current-funding-opportunities-type-1-diabetes-rfa) - [Full RFA: Call for Applications (PDF)](https://professional.diabetes.org/sites/dpro/files/2026-03/T1D-RFA-Call-for-Applications-FINAL.pdf) - [SmartSimple grant management system](https://diabetes.us-2.smartsimple.com/s_Login.jsp?lang=1&prole=0) - [ICTS LOI Application Instructions (PDF)](https://professional.diabetes.org/sites/dpro/files/2026-03/icts-loi-application-instruction-t1d2026.pdf) - [ICTS Full Proposal Instructions (PDF)](https://professional.diabetes.org/sites/dpro/files/2026-03/icts-full-proposal-instructions-t1d2026.pdf) - [ADA Research Programs main site](https://professional.diabetes.org/grants) --- ## Contact Information | Purpose | Contact | |----------------------|--------------------------------------------------------| | General inquiries | [grantquestions@diabetes.org](mailto:grantquestions@diabetes.org) | | ADA main phone | 1-800-DIABETES (800-342-2383) | | Funder homepage | [https://diabetes.org](https://diabetes.org) | ---

Innovative Clinical or Translational Science Award

Sign in to see full grant listing